Cephalon, H. Lundbeck Discontinue CEP-1347 Trial in Parkinson's Disease

Cephalon and H. Lundbeck A/S have discontinued their Phase II/III clinical trial of CEP-1347 in Parkinson's disease.

An independent data monitoring committee just completed a planned review of interim results and concluded that the data are unlikely to provide evidence of significant effect. There were no safety concerns.

The study was being conducted by the Parkinson Study Group, a nonprofit, cooperative group of Parkinson's disease experts from medical centers in the U.S. and Canada who are dedicated to improving treatment for persons affected by Parkinson's disease.